Search hospitals > Illinois > Chicago
Northwestern University
Claim this profileChicago, Illinois 60611
Global Leader in Parotid Gland Cancer
Global Leader in Cancer
Conducts research for Breast Cancer
Conducts research for Lymphoma
Conducts research for Adult T-Cell Leukemia/Lymphoma
1949 reported clinical trials
209 medical researchers
Summary
Northwestern University is a medical facility located in Chicago, Illinois. This center is recognized for care of Parotid Gland Cancer, Cancer, Breast Cancer, Lymphoma, Adult T-Cell Leukemia/Lymphoma and other specialties. Northwestern University is involved with conducting 1,949 clinical trials across 2,182 conditions. There are 209 research doctors associated with this hospital, such as Sunandana Chandra, Aparna Kalyan, Amy Paller, and Seth M. Pollack.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Cancer
Global LeaderStage IV
Stage III
HER2 positive
Top PIs
Sunandana ChandraNorthwestern University2 years of reported clinical research
Expert in Skin Cancer
Expert in Melanoma
22 reported clinical trials
31 drugs studied
Aparna KalyanNorthwestern University2 years of reported clinical research
Studies Parotid Gland Cancer
Studies Bile Duct Cancer
22 reported clinical trials
40 drugs studied
Amy PallerNorthwestern University7 years of reported clinical research
Studies Atopic Dermatitis
Studies Dermatitis
20 reported clinical trials
18 drugs studied
Seth M. PollackNorthwestern University2 years of reported clinical research
Studies Soft Tissue Sarcoma
Studies Uterine Leiomyosarcoma
19 reported clinical trials
29 drugs studied
Clinical Trials running at Northwestern University
Lung Cancer
Breast Cancer
Parotid Gland Cancer
Kidney Cancer
Chronic Lymphocytic Leukemia
Cancer
Non-Small Cell Lung Cancer
Breast cancer
Lymphoma
Skin Cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Northwestern University?
Where is Northwestern University located?
Who should I call to ask about financial aid or insurance network?
What insurance does Northwestern University accept?
What awards or recognition has Northwestern University received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.